1[1]JOHANSSON P.Epidemiology of the myeloproliferative disorders polycytothemia vera and essential thrombocythemia[J].Sem Thromb Haemost,2006,32(3):171-173. 被引量：1
2[2]BAXTER EJ,SCOTT LM,CAMPELL PJ,et al.Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative sid]sorders[J].Lancet,2005,365:1054-1061. 被引量：1
3[3]JAMES C,UGO V,Le COUEDIC JP,et al.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera[J].Nature,2005,434:1144-1148. 被引量：1
4[4]LIPPERT E,BOISSINOT M,KRALOVICS R,et al.The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera[J].Blood,2006,108:1865-1867. 被引量：1
5[5]RANDI ML,PUTTI MC,SCAPIN M,et al.Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative[J].Blood,2006,108:3600-3602. 被引量：1
6[6]VASSILIOU GS,CAMPBELL PJ,LI J,An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation[J].Haematologica,2006,91:1100-1104. 被引量：1
7[7]VILLEVAL JL,JAMES C,PISANI DF,et al.New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients[J].Sem Thromb Haemost,2006,32:341-351. 被引量：1
8[8]PATEL RK,LEA NC,HENEGHAN MA,et al.Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome[J].Gastroenterology,2006,130:2031-2038. 被引量：1
10[10]CERVANTES F,ALVAREZ-LARRAN A,TALARN C,et al.Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:actuarial probability,presenting characteristics and evolution in a series of of 195 patients[J].Br J Haematol,2002,118:786-790. 被引量：1
7Johansson P. Epidemiology of the myelop roliferative disorders poly cytothemia vera and essential thrombocythemia [ J ]. Semin Thromb Hemost, 2006,32 ( 3 ) : 171 - 173. 被引量：1
8Tefferi A,Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primarymyelofibrosis : recommendations from an adhoc international expert panel [ J ]. Blood, 2007,110(4) : 1092 - 1097. 被引量：1
9Wadleigh M ,Tefferi A. Classification and diagnosis of myelop roliferative neoplasms according to the 2008 World Health Organizationcriteria [ J ]. Int J Hematol, 2010,91 ( 2 ) : 174 - 179. 被引量：1
10Patel RK, Lea NC, Heneghan MA, et al. prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-chiari syndrome. Gastroenterology,2006,130:2031-2038. 被引量：1
